Literature DB >> 23942028

Serotonergic hallucinogens as translational models relevant to schizophrenia.

Adam L Halberstadt1, Mark A Geyer.   

Abstract

One of the oldest models of schizophrenia is based on the effects of serotonergic hallucinogens such as mescaline, psilocybin, and (+)-lysergic acid diethylamide (LSD), which act through the serotonin 5-HT(2A) receptor. These compounds produce a 'model psychosis' in normal individuals that resembles at least some of the positive symptoms of schizophrenia. Based on these similarities, and because evidence has emerged that the serotonergic system plays a role in the pathogenesis of schizophrenia in some patients, animal models relevant to schizophrenia have been developed based on hallucinogen effects. Here we review the behavioural effects of hallucinogens in four of those models, the receptor and neurochemical mechanisms for the effects and their translational relevance. Despite the difficulty of modelling hallucinogen effects in nonverbal species, animal models of schizophrenia based on hallucinogens have yielded important insights into the linkage between 5-HT and schizophrenia and have helped to identify receptor targets and interactions that could be exploited in the development of new therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23942028      PMCID: PMC3928979          DOI: 10.1017/S1461145713000722

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  185 in total

1.  Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors.

Authors:  J C Gewirtz; G J Marek
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

2.  Experimental psychiatry. II. Clinical and physio-chemical observations in experimental psychosis.

Authors:  M RINKEL; R W HYDE; H C SOLOMON; H HOAGLAND
Journal:  Am J Psychiatry       Date:  1955-06       Impact factor: 18.112

3.  Effects of varied doses of psilocybin on time interval reproduction in human subjects.

Authors:  Jirí Wackermann; Marc Wittmann; Felix Hasler; Franz X Vollenweider
Journal:  Neurosci Lett       Date:  2008-02-09       Impact factor: 3.046

4.  Temporal processing in schizophrenia: effects of task-difficulty on behavioral discrimination and neuronal responses.

Authors:  Deana B Davalos; Donald C Rojas; Jason R Tregellas
Journal:  Schizophr Res       Date:  2010-08-01       Impact factor: 4.939

5.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.

Authors:  Kirsten Krebs-Thomson; Erbert M Ruiz; Virginia Masten; Mahalah Buell; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

6.  A possible correlation between drug-induced hallucinations in man and a behavioural response in mice.

Authors:  S J Corne; R W Pickering
Journal:  Psychopharmacologia       Date:  1967

7.  The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.

Authors:  Gerard J Marek; Raul Martin-Ruiz; Allyson Abo; Francesc Artigas
Journal:  Neuropsychopharmacology       Date:  2005-12       Impact factor: 7.853

8.  Timing dysfunctions in schizophrenia span from millisecond to several-second durations.

Authors:  Christine A Carroll; Brian F O'Donnell; Anantha Shekhar; William P Hetrick
Journal:  Brain Cogn       Date:  2009-03-17       Impact factor: 2.310

9.  [Altered perception of temporal relations in schizophrenic psychoses].

Authors:  A Tenckhoff; H Tost; D F Braus
Journal:  Nervenarzt       Date:  2002-05       Impact factor: 1.214

10.  Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia.

Authors:  Katja Ludewig; Mark A Geyer; Franz X Vollenweider
Journal:  Biol Psychiatry       Date:  2003-07-15       Impact factor: 13.382

View more
  17 in total

1.  Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.

Authors:  Ignasi Oliveras; Ana Sánchez-González; Daniel Sampedro-Viana; Maria Antonietta Piludu; Cristóbal Río-Alamos; Osvaldo Giorgi; Maria G Corda; Susana Aznar; Javier González-Maeso; Cristina Gerbolés; Gloria Blázquez; Toni Cañete; Adolf Tobeña; Alberto Fernández-Teruel
Journal:  Psychopharmacology (Berl)       Date:  2017-02-02       Impact factor: 4.530

2.  Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Authors:  Simon D Brandt; Pierce V Kavanagh; Geraldine Dowling; Brian Talbot; Folker Westphal; Markus R Meyer; Hans H Maurer; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2016-04-21       Impact factor: 3.345

3.  Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges.

Authors:  Zackary A Cope; Adam L Halberstadt; Jordy van Enkhuizen; Aaron D Flynn; Michelle Breier; Neal R Swerdlow; Mark A Geyer; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2016-08-17       Impact factor: 4.530

4.  Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).

Authors:  Simon D Brandt; Pierce V Kavanagh; Brendan Twamley; Folker Westphal; Simon P Elliott; Jason Wallach; Alexander Stratford; Landon M Klein; John D McCorvy; David E Nichols; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2017-07-27       Impact factor: 3.345

5.  Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Authors:  Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

Review 6.  Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.

Authors:  David Baumeister; Georgina Barnes; Giovanni Giaroli; Derek Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-08

7.  Animal Models of Psychosis: Current State and Future Directions.

Authors:  Alexandra D Forrest; Carlos A Coto; Steven J Siegel
Journal:  Curr Behav Neurosci Rep       Date:  2014-06-01

Review 8.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

9.  Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Khoa Hoang; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2015-10-12       Impact factor: 3.345

10.  Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia.

Authors:  David A Martin; Danuta Marona-Lewicka; David E Nichols; Charles D Nichols
Journal:  Neuropharmacology       Date:  2014-04-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.